Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical trial

Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical trial

Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical trial for the development of KH-001 as first FDA-approved treatment for premature ejaculation

Kanna Health announces patent application publication for novel synthetic mesembrine-inspired alkaloids as treatments for neurology, psychiatric, and inflammation-related diseases

Kanna Health announces patent application publication for novel synthetic mesembrine-inspired alkaloids as treatments for neurology, psychiatric, and inflammation-related diseases

People | Product | Potential Special Edition on the World’s Indigenous People International Day

People | Product | Potential Special Edition on the World’s Indigenous People International Day

Kanna Health announces patent application publication for KH-001 as premature ejaculation treatment

Kanna Health announces patent application publication for KH-001 as premature ejaculation treatment